<scp>PFKFB4</scp> facilitates palbociclib resistance in oestrogen receptor‐positive breast cancer by enhancing stemness

Abstract

These findings not only demonstrated the novel mechanism underlying which ER⁺ BC cells resisted to palbociclib, but also provided a possible therapeutic strategy in the intervention of ER⁺ BC to overcome drug resistance.